Literature DB >> 3358630

Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture.

J Bartholeyns1, Y Lombard, P Poindron.   

Abstract

Normal resident peritoneal macrophages from BALB/c mice were continuously grown and expanded in vitro as non tumorigenic cells on a confluent layer of mesothelial cells. These peritoneal macrophages expanded in vitro (EPM) were very cytotoxic against EMT6 sarcoma, Abelson myeloma, EL4, and L929S cells in culture. This tumoricidal effect was fully expressed without further activation with bacterial lipopolysaccharides (LPS). In vivo, adoptive transfer of one million EPM to BALB/c mice bearing subcutaneous EMT6 sarcoma caused regression of the solid tumor. In contrast, macrophages produced by 10 days' culture of bone marrow stem cells, or freshly isolated from the peritoneal cavity of BALB/c mice, were not cytotoxic in vitro or in vivo. Local injection in the vicinity of the tumor as well as intravenous transplantation of EPM effectively inhibited tumor growth. This antitumoral effect was further enhanced by intraperitoneal injection of 2 micrograms LPS to the tumor bearing mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358630

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.

Authors:  A Faradji; A Bohbot; M Schmitt-Goguel; N Roeslin; S Dumont; M L Wiesel; C Lallot; M Eber; J Bartholeyns; P Poindron
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Interactions between human macrophages and tumor cells in three-dimensional cultures.

Authors:  R Audran; L Dazord; L Toujas
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

3.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.